Feasibility of amplicon-based targeted next-generation sequencing of colorectal cancer in endoscopic biopsies
10.3760/cma.j.issn.0529-5807.2018.07.004
- VernacularTitle: 靶向二代测序检测结直肠癌肠镜活检标本的可行性分析
- Author:
Yajian WANG
1
;
Ruirui JIANG
;
Haijing LIU
;
Bo ZHANG
;
Feng YE
;
Hong BU
Author Information
1. Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China
- Publication Type:Journal Article
- Keywords:
Colorectal neoplasms;
High-throughput nucleotide sequencing;
Endoscopy, gastrointestinal;
Specimen handling
- From:
Chinese Journal of Pathology
2018;47(7):499-504
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate whether small endoscopic biopsies of colorectal cancer were sufficient for quality and accurate mutational analysis by amplicon-based next-generation sequencing (NGS).
Methods:By using an amplicon-based targeted NGS panel for mutational detection on Illumina Miseq platform, a total of 109 formalin-fixed and paraffin-embedded (FFPE) endoscopic biopsies of colorectal cancer were retrospectively selected, based on specific histopathologic criteria, from January 2012 to June 2016 at West China Hospital of Sichuan University and Peking University Third Hospital. Twelve of these biopsies had corresponding FFPE surgical resection specimens. Quality control parameters of NGS testing were analyzed and NGS results were confirmed by other methods. Mutation calls of the 12 paired endoscopic biopsies and surgical resections were compared.
Results:Of the endoscopic biopsy specimens, 97.2% (106/109) had sufficient DNA and qualified sequencing library. NGS generated excellent sequencing data, with a median of 848× for median read depth and 95.7% for uniformity. The success rate of NGS was 95.4% (104/109). Conventional methods confirmed the results of NGS for KRAS and BRAF, and the concordance rate was 100.0%. The clinically actionable mutations detected in the 12 paired endoscopic biopsies and surgical resections were concordant.
Conclusion:FFPE endoscopic biopsies of colorectal cancer is suitable for targeted NGS, providing quality sequencing data and accurate mutational information to guide targeted therapy.
